News
The company will resume the Phase II trial, initially at a lower dose and with a new immunomodulatory regimen.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback